R-23-NP020

R-23-NP020 is a topical therapeutic candidate developed by Dong-A Pharmaceutical for the treatment and management of acne scars. Currently in the registration phase (NDA/BLA filed), the product is part of Dong-A's consumer health pipeline. It is designed to improve the appearance of hypertrophic and keloid scars resulting from acne, likely by promoting skin regeneration and normalizing collagen structure. While specific formulation details for this project code are not fully disclosed, it is positioned as a dermatological intervention to address post-inflammatory hyperpigmentation and scar tissue formation, potentially utilizing a gel-based delivery system similar to the company's established Noscarna brand.